RedCloudBio

RedCloudBio is an innovative pharmaceutical company with leading development technologies and extensive experience in the field of small molecule drug research and development. RedCloudBio has established research and development centers in Shanghai and Beijing, possessing a small molecule drug R&D platform centered on structural pharmacology and integrating cutting-edge computational technologies such as molecular dynamics, computational chemistry, and artificial intelligence (AI), along with global clinical development capabilities. RedCloudBio has accumulated a wealth of structural data and algorithmic models in multiple target areas focused on clinical needs and has built several pipelines for the development of small molecule precision drugs, covering treatment areas such as oncology, rare diseases, and other fields with significant unmet clinical needs. Among these, H002, a novel small molecule drug independently developed by the company, has entered the global clinical research stage and is expected to become a new generation EGFR inhibitor with unique clinical advantages for treating various non-small cell lung cancers mediated by EGFR activating mutations.